Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units ("RSUs") to one newly hired employee.
2024年7月1日，马萨诸塞州查尔斯顿（GLOBE NEWSWIRE）—— Solid Biosciences Inc.（纳斯达克：SLDB）（“公司”）是一家生命科学公司，致力于开发用于神经肌肉和心脏疾病的精准基因药物，今天宣布向一名新雇员授予11847个受限股票单位（“RSUs”）。
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee's continued service with the Company through each applicable vesting date.
股票将在授予日起到第四个周年纪念日的四个等额分期归属。权益奖励的归属取决于员工在每个适用的归属日期之前继续服务于公司。
This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
该批股票是根据公司的2024年引诱性股票激励计划授予，并根据纳斯达克上市规则5635(c)(4)与雇员的就业接受有关而作为诱因。
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
关于固体生物科学（Solid Biosciences）
Solid Biosciences 是一家生命科学公司，专注于推进一系列基因治疗候选药物，包括用于治疗杜兴氏肌萎缩症 (Duchenne) 的 SGT-003、用于治疗儿茶酚胺多形性室性心动过速 (CPVT) 的 SGT-501、用于治疗BAG3介导的扩张型心肌病的AVB-401，以及其他用于治疗致命心脏病的资产。Solid正在推进其在罕见的神经肌肉和心脏疾病领域的各种管线，在科学、技术、疾病管理和护理方面汇集专家。以患者为中心，由直接受到影响的人创立，Solid的使命是改善患有这些毁灭性疾病的患者的日常生活。更多信息，请访问www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Solid Biosciences投资者联系方式：
Nicole Anderson
投资者关系和企业传播董事Nicole Anderson
solid biosciences 公司。
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
媒体联系人：
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
Source: Solid Biosciences Inc.
来源：Solid Biosciences Inc.